Molecular dynamic simulations unveil conformational dynamics of SARS-CoV-2 spike protein RBD and ACE2 receptor

NewsGuard 100/100 Score

Researchers from the Federal University of Para, Brazil, presented a systematic analysis of the affinity and conformational dynamics between the binding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) spike (S) protein and the host angiotensin-converting enzyme 2 (ACE2) receptor.

Study: Assessment of Mutations on RBD in the Spike Protein of SARS-CoV-2 Alpha, Delta and Omicron Variants. Image Credit: Akarat Jarernthanawut/Shutterstock

Study: Assessment of Mutations on RBD in the Spike Protein of SARS-CoV-2 Alpha, Delta and Omicron Variants. Image Credit: Akarat Jarernthanawut/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The researchers used accelerated molecular dynamics (aMD) simulations and free energy calculations to assess whether infectivity and transmission of SARS-CoV-2-related variants were related to binding to the receptor.

The study has been posted to the Research Square* preprint server and is currently under review at Scientific Reports journal.

Background

SARS-CoV-2 S glycoprotein contains S1 and S2 subunits and is composed of a total of 1,273 residues.  The interaction between the RBD located in the S1 domain with ACE2 guides viral entry into the cell. S1 RBD underwent conformational changes in specific residues that revealed determinants of receptor binding.

Evidence from several studies suggested that mutations involving K417N, S477N, T478K, E484A, and N501Y in SARS-CoV-2 Omicron and other variants conferred viral escape capabilities or better binding affinity to ACE2 receptor and hence increased reinfection risk.

To analyze this further, the current study explored the effect of mutations in the S RBD of the SARS-CoV-2 Alpha, Delta, and Omicron variants on binding affinity to the human ACE2 receptor.

Study design

In this study, the authors performed classical molecular dynamics (cMD) simulations to assess average dihedral and total protein energies as a reference for aMD simulations. They carried out an aMD simulation of 200 ns to explore conformations over time for the RBDWT-ACE2, RBDAlpha-ACE2, RBDDelta-ACE2, and RBDOmicron-ACE2 complex systems.

The root-mean-square fluctuations (RMSF) analysis revealed the flexibility of each residue in the protein-protein complex system. Principal components analysis (PCA) allowed diagonalization of the covariance matrix to obtain the principal components. PCA graphs were built through combinations of PC1 vs PC2, PC2 vs PC3, and PC3 vs PC1 in which the clusters demonstrated two possible states for all systems in PC1 vs PC2.

The authors calculated binding free energy for RBD-ACE2 complexes of different SARS-CoV-2 variants to estimate SARS-CoV-2 affinity for human ACE2 receptor and potential risk of immune invasion by different SARS-CoV-2 variants. Decomposition energy assessed energy contribution of amino acid with the RBD and ACE2 binding, while the molecular mechanics, the generalized Born model, and solvent accessibility (MMGBSA) method implemented in AMBER calculated these free energies based on the greatest stability of the aMD trajectory.

Findings

The aMD simulations showed that RMSD of RBDWT-ACE2, RBDAlpha-ACE2, and RBDDelta-ACE2 complexes were in the 1 to 3 Å fluctuation range. However, the RBDOmicron-ACE2 complex represented different variations in the 1 to 4 Å range. Intriguingly, all the RBD-ACE2 complex systems had achieved structural equilibrium.

The RMSF analysis showed the greatest fluctuation of ACE2 in the regions of 123 to 178,  395 to 425, and 248 to 368 residues that move to interact with viral RBD. RBDalpha-ACE2 showed lower fluctuation as compared to the RBDWT, RBDDelta, and RBDOmicron.

The essential dynamic analysis demonstrated clusters in PCA graphs showing two probable states for all systems in PC1 vs PC2. However, the Alpha variant showed a higher cluster number wherein each time gap was differentiated into small clusters.

The initial structure of the RBDOmicron system differed from the final structure resulting in variations of the aMD structures. The RBDWT and the RBDOmicron strains elucidated substantial fluctuations in conformation; however, the RBDAlpha variant had greater stability.

The RBDOmicron showed the greatest binding affinity to the human ACE2 receptor and similar conformational fluctuation as compared to the other variants.  RBDOmicron showed a higher binding free energy (-75.4 kcal/mol) as compared to RBDDelta (-66.1 kcal/mol), RBDAlpha (62.7836 kcal/mol), and the RBDWT type (-59.7 kcal/mol).

Decomposition energy calculation showed that in RBDOmicron, mutations N440K, T478K, Q493R, and Q498R resulted in favorable interaction between RBDOmicron and ACE2.  Interestingly all mutations in RBDOmicron included positively charged residues of Lys or Arg. The Omicron K478 mutation (decomposition energy, -85.8 kcal/mol) had a stabilizing effect while T478 mutation in RBDWT (0.7 kcal/mol) had a destabilizing effect.

The T478K mutation was located in a solvent-oriented region and allowed ACE2 interaction due to the side chain increase. The Q493R substitution allowed a favorable interaction with Asp38 and Glu35 negatively charged residues of ACE2 increasing the S protein binding. N440K mutation located in the region focused on solvent whereas Q498R mutation improved protein-protein interaction and this contribution was 24 times higher as compared to RBDWT.

The N501Y mutation in RBDAlpha showed similar decomposition energy as compared to RBDWT. Hence, conformational stability in RBDAlpha was responsible for its better binding to ACE2. In RBDDelta, the L352R and T478K mutations had a higher energetic contribution of
-90.5 and -82.6 kcal/mol, respectively, highlighting increased binding improvement with the ACE2 receptor.

Conclusion

The findings of this study demonstrated that the SARS-CoV-2 RBDOmicron-ACE2 complex elucidated identical fluctuations as compared to the S protein from wild type, Alpha, and Delta strains.

Overall, mutations in the RBDOmicron increased S protein binding affinity for ACE2 and further mutations of uncharged residues to positively charged Lys and arg residues in a key position with RBD. This accounts for the high transmissibility of the SARS-CoV-2 Omicron variant compared to other variants.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 13 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Sangeeta Paul

Written by

Sangeeta Paul

Sangeeta Paul is a researcher and medical writer based in Gurugram, India. Her academic background is in Pharmacy; she has a Bachelor’s in Pharmacy, a Master’s in Pharmacy (Pharmacology), and Ph.D. in Pharmacology from Banasthali Vidyapith, Rajasthan, India. She also holds a post-graduate diploma in Drug regulatory affairs from Jamia Hamdard, New Delhi, and a post-graduate diploma in Intellectual Property Rights, IGNOU, India.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Paul, Sangeeta. (2023, May 13). Molecular dynamic simulations unveil conformational dynamics of SARS-CoV-2 spike protein RBD and ACE2 receptor. News-Medical. Retrieved on April 20, 2024 from https://www.news-medical.net/news/20220322/Molecular-dynamic-simulations-unveil-conformational-dynamics-of-SARS-CoV-2-spike-protein-RBD-and-ACE2-receptor.aspx.

  • MLA

    Paul, Sangeeta. "Molecular dynamic simulations unveil conformational dynamics of SARS-CoV-2 spike protein RBD and ACE2 receptor". News-Medical. 20 April 2024. <https://www.news-medical.net/news/20220322/Molecular-dynamic-simulations-unveil-conformational-dynamics-of-SARS-CoV-2-spike-protein-RBD-and-ACE2-receptor.aspx>.

  • Chicago

    Paul, Sangeeta. "Molecular dynamic simulations unveil conformational dynamics of SARS-CoV-2 spike protein RBD and ACE2 receptor". News-Medical. https://www.news-medical.net/news/20220322/Molecular-dynamic-simulations-unveil-conformational-dynamics-of-SARS-CoV-2-spike-protein-RBD-and-ACE2-receptor.aspx. (accessed April 20, 2024).

  • Harvard

    Paul, Sangeeta. 2023. Molecular dynamic simulations unveil conformational dynamics of SARS-CoV-2 spike protein RBD and ACE2 receptor. News-Medical, viewed 20 April 2024, https://www.news-medical.net/news/20220322/Molecular-dynamic-simulations-unveil-conformational-dynamics-of-SARS-CoV-2-spike-protein-RBD-and-ACE2-receptor.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial